Progen
Biopharmaceutical company developing multi-target fusion-protein therapeutics and targeted cytokine technologies. Uses a proprietary fusion-protein platform optimized for multi-targeting and extended in vivo durability to advance programs in metabolic disease (obesity/diabetes), immune-oncology and autoimmune indications. Activities include platform R&D, mammalian cell line and bioprocess development, preclinical evaluation in metabolic and liver disease models, and multi-center clinical trials with licensing and partnership-driven commercialization.
Industries
Nr. of Employees
small (1-50)
Progen
7F, Bio Innovation Park, 172 Magokjungang-ro, Gangseo-gu, Seoul, Republic of Korea
Patents
Products
PG-102
Fusion-protein therapeutic combining GLP-1 and GLP-2 receptor agonist activities using a multi-target fusion platform; developed for obesity, type 2 diabetes and related metabolic/liver indications.
NTIG platform (technology)
Proprietary multi-target fusion-protein platform used to extend durability and enable simultaneous receptor targeting for therapeutic proteins and cytokines.
PG-102
Fusion-protein therapeutic combining GLP-1 and GLP-2 receptor agonist activities using a multi-target fusion platform; developed for obesity, type 2 diabetes and related metabolic/liver indications.
NTIG platform (technology)
Proprietary multi-target fusion-protein platform used to extend durability and enable simultaneous receptor targeting for therapeutic proteins and cytokines.
Services
Licensing of fusion-protein platform technology and transfer of cell-line and culture technologies to partners.
Joint development arrangements to advance oral formulations and immuno-oncology/immunotherapy candidates from discovery to clinic.
Licensing of fusion-protein platform technology and transfer of cell-line and culture technologies to partners.
Joint development arrangements to advance oral formulations and immuno-oncology/immunotherapy candidates from discovery to clinic.
Expertise Areas
- Fusion-protein platform development
- Engineered cytokine therapeutics
- Peptide dual-agonist discovery
- Preclinical metabolic disease models (obesity/diabetes/NASH)
Key Technologies
- Multi-target fusion protein platforms
- Engineered cytokine targeting
- Bispecific / dual-agonist peptides
- Albumin/half-life extension fusion strategies
News & Updates
Announcement of initiation of Phase II multi-site clinical trial for a next-generation obesity and diabetes treatment.
Press release reporting up to 8.7% weight reduction with weekly dosing over four weeks in early clinical testing.
Company press release noting completion of dosing in Phase 1c and announcement that final results will be presented in early 2025.
Eighteen licensing and technology-transfer deals related to platform and application technologies (deal list includes multiple cell-line and platform licenses).
Announcement of initiation of Phase II multi-site clinical trial for a next-generation obesity and diabetes treatment.
Press release reporting up to 8.7% weight reduction with weekly dosing over four weeks in early clinical testing.
Company press release noting completion of dosing in Phase 1c and announcement that final results will be presented in early 2025.
Eighteen licensing and technology-transfer deals related to platform and application technologies (deal list includes multiple cell-line and platform licenses).